Haemonetics Corporation
HAE
$54.10
$0.000.00%
NYSE
| 06/28/2025 | 03/29/2025 | 12/28/2024 | 09/28/2024 | 06/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -4.40% | -3.70% | 3.66% | 8.59% | 7.98% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.40% | -3.70% | 3.66% | 8.59% | 7.98% |
| Cost of Revenue | -17.43% | -14.84% | -1.78% | 4.53% | 9.05% |
| Gross Profit | 7.01% | 5.41% | 8.10% | 12.10% | 7.06% |
| SG&A Expenses | -1.41% | 1.36% | -0.34% | -3.09% | 8.19% |
| Depreciation & Amortization | -8.65% | 8.35% | 76.96% | 69.81% | 66.88% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.08% | -6.86% | 1.87% | 4.45% | 10.68% |
| Operating Income | 27.38% | 15.10% | 12.07% | 35.35% | -4.98% |
| Income Before Tax | -3.31% | 202.11% | 13.37% | 36.16% | -9.45% |
| Income Tax Expenses | 33.55% | 318.64% | -2.85% | 37.22% | -20.93% |
| Earnings from Continuing Operations | -11.32% | 184.68% | 20.02% | 35.82% | -6.50% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.32% | 184.68% | 20.02% | 35.82% | -6.50% |
| EBIT | 27.38% | 15.10% | 12.07% | 35.35% | -4.98% |
| EBITDA | 16.95% | 14.51% | 15.28% | 32.13% | 4.67% |
| EPS Basic | -6.11% | 193.92% | 21.16% | 35.38% | -7.23% |
| Normalized Basic EPS | 2.77% | 5.16% | 0.87% | 25.83% | 11.45% |
| EPS Diluted | -5.41% | 194.65% | 21.31% | 37.50% | -7.50% |
| Normalized Diluted EPS | 3.52% | 5.83% | 1.52% | 26.64% | 11.83% |
| Average Basic Shares Outstanding | -5.56% | -3.14% | -0.95% | 0.34% | 0.79% |
| Average Diluted Shares Outstanding | -6.23% | -3.76% | -1.57% | -0.30% | 0.44% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |